Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs

The New York Times – Business:

Rasonque, the new pancreatic cancer treatment from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades.

Rebecca Robbins
Author: Rebecca Robbins

This post first appeared in The New York Times – Business. Read the original article.

Written by

Rebecca Robbins

in

Cancer, Clinical Trials, Drugs (Pharmaceuticals), Elderly, Health Insurance and Managed Care, Immunotherapy, Institute for Clinical and Economic Review, Longevity, Pancreatic Cancer, Prices (Fares, Fees and Rates), Revolution Medicines Inc
←At the Tupac Trial, Old Rumors Still Trail Sean Combs
Democrats Have a Trump Card for Attacks On Wokeness→

More posts

  • 18 Celebrities Who Discovered Their Partners’ Cheating In Heartbreaking Ways

  • The 8 Best James Bond Films

  • Washington governor decries ‘out-of-control’ ICE at Seattle airport

  • FBI’s national crime database targeted in hack, Trump says

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube